Cetera Investment Advisers Has $19.44 Million Holdings in Cencora, Inc. $COR

Cetera Investment Advisers trimmed its stake in Cencora, Inc. (NYSE:COR) by 8.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,831 shares of the company’s stock after selling 5,673 shares during the period. Cetera Investment Advisers’ holdings in Cencora were worth $19,439,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Atlantic Edge Private Wealth Management LLC grew its position in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Cencora in the 1st quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Cencora during the 1st quarter worth approximately $39,000. Hantz Financial Services Inc. lifted its position in Cencora by 712.0% in the second quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Cencora during the second quarter worth $61,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.9%

Shares of NYSE COR opened at $361.80 on Wednesday. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $369.00. The company has a 50-day moving average of $323.97 and a two-hundred day moving average of $303.25. The company has a market cap of $70.14 billion, a PE ratio of 37.22, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the prior year, the firm earned $3.34 earnings per share. Cencora’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 41,544 shares of company stock worth $12,230,941 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on COR. Wells Fargo & Company upped their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. UBS Group boosted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, TD Cowen boosted their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.